A recently developed modified BCl-2 inhibitor, ABT-199, shows high selectivity towards BCL-2 without inhibiting BCL-XL or BCL-w and is currently approved for chronic lymphocytic leukemia. This evidence concerns the gene BCL2 and B-cell chronic lymphocytic leukemia.